Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrating ex vivo drug sensitivity and genetic mutation analysis improves prediction of chemotherapy response in acute myeloid leukemia.

Functional & integrative genomics - 29 May 2026

Li Wěi, Ji Min, Li Wei, Zhou Ying, Jia Ruinan, Wen Xin, Jin Shumin, Hao Yiping, Dai Min, Xu Shumei, Zhou Qirui, Jiang Huihui, Ji Chunyan, Ye Jingjing

Abstract excerpt

Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy characterized by extensive genomic alterations and molecular diversity, posing significant therapeutic challenges. Current treatment strategies lack precise predictive biomarkers for chemotherapy response, highlighting the need for tools to guide precision therapy. In this study, we evaluated in vitro chemotherapy sensitivity in bone marrow...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to Drug Resistance, Neoplasm

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 42209825
DOI: 10.1007/s10142-026-01895-z
PMCID: PMC13219155

Genes

DNMT3A

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrating ex vivo drug sensitivity and genetic mutation analysis improves prediction of chemotherapy response in acute myeloid leukemia.PMID 42209825Read ↗

Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.Semantic proximity Read ↗

Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trialSemantic proximity Read ↗

Mutation Patterns Predict Drug Sensitivity in Acute Myeloid LeukemiaSemantic proximity Read ↗

Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AMLSemantic proximity Read ↗

Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New AgentsSemantic proximity Read ↗

Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia TherapySemantic proximity Read ↗

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination TherapiesSemantic proximity Read ↗

Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid LeukemiaSemantic proximity Read ↗

Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemiaSemantic proximity Read ↗

Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registrySemantic proximity Read ↗

Drug response profiling guides precision therapy in relapsed and refractory childhood acute lymphoblastic leukemiaSemantic proximity Read ↗

Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.